A new study published in the journal Frontiers in Neuroscience finds that cannabidiol (CBD) may play a significant role in slowing the early progression of Alzheimer’s disease. The team administered daily dietary CBD to genetically engineered Alzheimer’s mice and wild-type controls, analyzing brain regions, blood samples, and behavior. They found more than 1,000 molecular markers tied to Alzheimer’s onset, but over 75% of these were either reversed or eliminated when CBD was introduced. The findings suggest Alzheimer’s onset involves interconnected disruptions in inflammation, oxidative stress, insulin resistance, and lipid metabolism—factors that CBD may help regulate. While more research is needed in humans, the results strengthen the case for CBD as a candidate for future Alzheimer’s therapies.